Biotech | March 03, 2022
Medix Biochemica announces expansion of its porfolio
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
Serina has over 17 years of experience in the biopharmaceutical industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
In this role, Jeffrey DeAlmeida takes responsibility for BASF’s global pharmaceutical solutions portfolio and the Nutrition & Health business in North and South America
Mankind Pharma has agreed to retain Panacea Biotec’s sales and marketing team engaged in this business
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Subscribe To Our Newsletter & Stay Updated
